arrow
C

Cara Mathews

women and infants hospital
H指数:34
被引数:8,610

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer

基于NRG GY017的局部晚期宫颈癌免疫治疗联合化疗放射治疗中的影像引导近距离放射治疗质量保证研究

2026-01-011
OAAI
Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma

乳腺癌和胃癌HER2免疫组化(IHC)评分标准在子宫内膜癌评估中的比较

2025-11-130
OAAI
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel

质量调整的无疾病进展症状或治疗毒性的时间,在原发性晚期或复发性子宫内膜癌患者中使用dostarlimab联合卡铂-紫杉醇治疗与卡铂-紫杉醇治疗相比

2025-05-210
OA
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third- line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial

mirvetuximab soravtansine在FRα阳性、三线及以后、复发性铂敏感卵巢癌中的疗效与安全性:单臂II期PICCOLO试验

2025-03-010
OAAI
Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis

Olaparib通过BRCA突变和同源重组缺陷治疗铂敏感复发性卵巢癌: 2期光研究最终总生存分析

CANCER
IF5.1
2025-01-160
OAAI
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers

Cyclin E1/CDK2的激活定义了妇科癌症中WEE1激酶抑制的关键易损性。

2025-01-040
OA
Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy

ENGOT-EN6-NSGO/GOG-3031/RUBY试验中接受随访免疫治疗的局部晚期或复发性子宫内膜癌(pA/rEC)患者的术后进展生存结局。

2024-09-010
PRE
Impact of investigator-assessed response on overall survival (OS) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial

研究者评估的反应对原发性晚期或复发性子宫内膜癌(pA/rEC)患者总体生存期(OS)的影响:ENGOT-EN6-NSGO/GOG3031/RUBY试验

2024-09-010
PRE
Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial

Мирветуксимаб соравтансин (MIRV) 在复发铂敏感卵巢癌(PSOC)且叶酸受体-α(FRα)高表达中的应用:PICCOLO 试验的结果

2024-09-015
PRE
Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
2023-10-017
PRE
Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
2023-07-011
PRE
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
2023-06-2618
OAAI
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
2023-06-08246
OA
Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

新诊断的晚期卵巢癌和BRCA突变患者7年随访时维持Olaparib的总生存率: SOLO1/GOG 3004试验

2023-01-013
OA
Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
2022-09-016
OAAI